

Nashiru Billa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6461228/publications.pdf>

Version: 2024-02-01

42
papers

1,219
citations

430843

18
h-index

377849

34
g-index

42
all docs

42
docs citations

42
times ranked

1762
citing authors

#	ARTICLE	IF	CITATIONS
1	Nanotechnology-based drug delivery systems for Alzheimer's disease management: Technical, industrial, and clinical challenges. <i>Journal of Controlled Release</i> , 2017, 245, 95-107.	9.9	156
2	Cellular uptake and anticancer effects of mucoadhesive curcumin-containing chitosan nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2014, 116, 228-236.	5.0	127
3	An Evaluation of Curcumin-Encapsulated Chitosan Nanoparticles for Transdermal Delivery. <i>AAPS PharmSciTech</i> , 2019, 20, 69.	3.3	109
4	Curcumin-containing chitosan nanoparticles as a potential mucoadhesive delivery system to the colon. <i>Pharmaceutical Development and Technology</i> , 2013, 18, 591-599.	2.4	99
5	Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118775.	5.2	61
6	Mucoadhesive Chitosan-Pectinate Nanoparticles for the Delivery of Curcumin to the Colon. <i>AAPS PharmSciTech</i> , 2017, 18, 1009-1018.	3.3	55
7	Mucoadhesive chitosan-coated nanostructured lipid carriers for oral delivery of amphotericin B. <i>Pharmaceutical Development and Technology</i> , 2019, 24, 504-512.	2.4	55
8	Gamma-scintigraphic study of the gastrointestinal transit and in vivo dissolution of a controlled release diclofenac sodium formulation in xanthan gum matrices. <i>International Journal of Pharmaceutics</i> , 2000, 201, 109-120.	5.2	49
9	An augmented delivery of the anticancer agent, curcumin, to the colon. <i>Reactive and Functional Polymers</i> , 2018, 123, 54-60.	4.1	41
10	Pharmacokinetic and anti-colon cancer properties of curcumin-containing chitosan-pectinate composite nanoparticles. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2018, 29, 2281-2298.	3.5	38
11	Lipid Effects on Expulsion Rate of Amphotericin B from Solid Lipid Nanoparticles. <i>AAPS PharmSciTech</i> , 2014, 15, 287-295.	3.3	29
12	Courier properties of modified citrus pectinate-chitosan nanoparticles in colon delivery of curcumin. <i>Colloids and Interface Science Communications</i> , 2019, 32, 100192.	4.1	29
13	A Gastrointestinal Transit Study on Amphotericin B-Loaded Solid Lipid Nanoparticles in Rats. <i>AAPS PharmSciTech</i> , 2015, 16, 871-877.	3.3	26
14	Antifungal and Mucoadhesive Properties of an Orally Administered Chitosan-Coated Amphotericin B Nanostructured Lipid Carrier (NLC). <i>AAPS PharmSciTech</i> , 2019, 20, 136.	3.3	26
15	Formation and characterization of pDNA-loaded alginate microspheres for oral administration in mice. <i>Journal of Bioscience and Bioengineering</i> , 2012, 113, 133-140.	2.2	25
16	A dual-application poly (<sc>dl</sc>-lactic-co-glycolic) acid (PLGA)-chitosan composite scaffold for potential use in bone tissue engineering. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2017, 28, 1966-1983.	3.5	23
17	Prospects of Curcumin Nanoformulations in Cancer Management. <i>Molecules</i> , 2022, 27, 361.	3.8	19
18	Simple liquid chromatographic method for the determination of naltrexone in human plasma using amperometric detection. <i>Biomedical Applications</i> , 1997, 701, 140-145.	1.7	18

#	ARTICLE	IF	CITATIONS
19	Cross-Linked Dependency of Boronic Acid-Conjugated Chitosan Nanoparticles by Diols for Sustained Insulin Release. <i>Pharmaceutics</i> , 2016, 8, 30.	4.5	18
20	Pharmacokinetics and tissue distribution of an orally administered mucoadhesive chitosan-coated amphotericin B-Loaded nanostructured lipid carrier (NLC) in rats. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2020, 31, 141-154.	3.5	18
21	Practicality of 3D Printed Personalized Medicines in Therapeutics. <i>Frontiers in Pharmacology</i> , 2021, 12, 646836.	3.5	18
22	Improved Bioavailability of Poorly Soluble Drugs through Gastrointestinal Muco-Adhesion of Lipid Nanoparticles. <i>Pharmaceutics</i> , 2021, 13, 1817.	4.5	18
23	An evaluation of tocotrienol ethosomes for transdermal delivery using Strat-M [®] membrane and excised human skin. <i>Pharmaceutical Development and Technology</i> , 2021, 26, 243-251.	2.4	17
24	Solid Dispersion Formulations by FDM 3D Printing—A Review. <i>Pharmaceutics</i> , 2022, 14, 690.	4.5	17
25	Using Nanoparticle Tracking Analysis (NTA) to Decipher Mucoadhesion Propensity of Curcumin-Containing Chitosan Nanoparticles and Curcumin Release. <i>Journal of Dispersion Science and Technology</i> , 2014, 35, 1201-1207.	2.4	16
26	Curcumin and Derivatives in Nanoformulations with Therapeutic Potential on Colorectal Cancer. <i>AAPS PharmSciTech</i> , 2022, 23, 115.	3.3	13
27	Correlating Physicochemical Properties of Boronic Acid-Chitosan Conjugates to Glucose Adsorption Sensitivity. <i>Pharmaceutics</i> , 2013, 5, 69-80.	4.5	12
28	Lyophilized Drug-Loaded Solid Lipid Nanoparticles Formulated with Beeswax and Theobroma Oil. <i>Molecules</i> , 2021, 26, 908.	3.8	10
29	Physicomechanical properties of sintered scaffolds formed from porous and protein-loaded poly(DL-lactic-co-glycolic acid) microspheres for potential use in bone tissue engineering. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2015, 26, 796-811.	3.5	9
30	Is Curcumin at the Threshold of Therapeutic Effectiveness on Patients with Colon Cancer?—A Systematic Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 707231.	3.5	9
31	Correlating gastric emptying of amphotericin B and paracetamol solid lipid nanoparticles with changes in particle surface chemistry. <i>International Journal of Pharmaceutics</i> , 2017, 517, 42-49.	5.2	8
32	PLGA-Gold Nanocomposite: Preparation and Biomedical Applications. <i>Pharmaceutics</i> , 2022, 14, 660.	4.5	8
33	Comparative Bioavailability Study of a Generic Naltrexone Tablet Preparation. <i>Drug Development and Industrial Pharmacy</i> , 1999, 25, 353-356.	2.0	7
34	Properties of An Oral Nanoformulation of A Molecularly Dispersed Amphotericin B Comprising A Composite Matrix of Theobroma Oil and Bee™ Wax. <i>Nanomaterials</i> , 2014, 4, 905-916.	4.1	7
35	Effect of Food Status on the Gastrointestinal Transit of Amphotericin B-Containing Solid Lipid Nanoparticles in Rats. <i>AAPS PharmSciTech</i> , 2016, 17, 1060-1066.	3.3	7
36	Multiboronic acid-conjugated chitosan scaffolds with glucose selectivity to insulin release. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2017, 28, 781-793.	3.5	7

#	ARTICLE	IF	CITATIONS
37	Monitoring model drug microencapsulation in PLGA scaffolds using X-ray powder diffraction. Saudi Pharmaceutical Journal, 2016, 24, 227-231.	2.7	4
38	Effect of volume of porogens on the porosity of PLGA scaffolds in pH-controlled environment. Pharmaceutical Development and Technology, 2018, 23, 207-210.	2.4	4
39	Soliciting the Oral Route as a Logical Approach to Managing Colon Cancer. Frontiers in Bioengineering and Biotechnology, 2021, 9, 645923.	4.1	2
40	Gastrointestinal Delivery of APIs from Chitosan Nanoparticles. , 0, , .		2
41	Characterization and ex vivo evaluation of curcumin nanoethosomes for melanoma treatment. Pharmaceutical Development and Technology, 2021, , 1-11.	2.4	2
42	A validated reverse-phase high performance liquid chromatography (RP-HPLC) method for the quantification of Gamma-tocotrienol in tocotrienol rich fractions of crude palm oil. Current Nutrition and Food Science, 2021, 17, .	0.6	1